1. Introduction {#sec1-1}
===============

Chronic Obstructive Pulmonary Disease (COPD) is a chronic disease that causes persistent airflow obstruction. The airflow obstruction in this disease is generally progressive ([@ref16]). COPD has two clinical phases (stable phase and exacerbation phase), both of which are associated with inflammation ([@ref5]). Smoking, passive smoking, reactivity of airways, occupational factors and air pollution are the risk factors of COPD ([@ref19]). Independent risk factors for COPD are male gender, advanced age, low socioeconomic status, occupational exposure and cigarette smoking ([@ref6]).

Based on the World Health Organization estimation, COPD will be the third cause of mortality in the world in 2020 ([@ref17]). Ninety percent of COPD deaths occur in low and middle income countries ([@ref17]). In European countries, depending on the age of participants, the methods used and the location, the prevalence of COPD ranged from 2.1% to 26.1% ([@ref3]). It was 8.9% in India (from 6.2% to 13.5%; based on spirometry) ([@ref1]), 3.02% in the Netherlands (in a population-based study including subjects ≥ 40) (8), 17.4% in Copenhagen (aged 35 years or older) ([@ref9] and 3.7% in Abu Dhabi (in 40-80 year old subjects) ([@ref2]).

Nowadays, the attention to nonskeletal effects of vitamin D has been increased ([@ref14]). An association between pulmonary function and serum vitamin D levels has been reported in some studies. It has been reported that vitamin D deficiency correlates with severity of COPD ([@ref12]). Also, in some studies, it has been declared that COPD patients had a raised risk for vitamin D deficiency ([@ref18], [@ref22]). Likewise, in one study, it has been stated that total vitamin D intake was negatively associated with COPD ([@ref20]).

According to previous studies, the effect of levels vitamin D is controversial on COPD exacerbation and FEV1. This study aimed to evaluate the effect of vitamin D intake on COPD exacerbation and FEV1 in the patients with severe and very severe COPD.

2. Method {#sec1-2}
=========

This double-blind, placebo-controlled, randomized clinical trial was done in Ashayer university hospital in Khorramabad in 2012. The Ethics and Research Committee of Lorestan University of Medical Sciences approved this study. Furthermore, we obtained signed informed consents from all the participants. This study has been recorded in Iranian Registry of Clinical Trials at [www.irct.ir](http://www.irct.ir) as a clinical trial (IRCT2012071810332N1). Eighty-eight patients with severe and very severe COPD were randomly selected from those who recoursed to the internal medicine clinic of Ashayer hospital. Severe and very severe COPD were defined as Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines ([@ref8]). The selected patients were allocated to the study and placebo groups by simple random sampling method. The patients in both the groups received the routine treatment for COPD. Along with the routine treatment, the study group received 100,000 IU of oral vitamin D per month, for 6 months. In contrast, the placebo group received oral placebo for 6 months. Before the study, forced expiratory volume in 1 second (FEV1) was determined, and the number of COPD exacerbations during the last 6 months was recorded in the both groups. After 6 months of treatment, FEV1 was determined, and the number of COPD exacerbations during the study span was evaluated in the both groups. The patients received a telephone call every 2 months to assess respiratory symptoms consistent with a COPD exacerbation. The definition of COPD exacerbation was either the presence of 2 or more of these major symptoms (increase in sputum purulence, sputum volume or dyspnea) or any of major symptoms accompanied by any of minor symptoms (increase in nasal discharge, wheeze, sore throat, cough or fever) for at least two consecutive days ([@ref8]).

2.1 Statistics {#sec2-1}
--------------

The data was analyzed using the SPSS computer software and paired t-test, independent t-test, non-parametric t-test and Pearson correlation coefficients. The P-values\<0.05 were considered statistically significant.

3. Results {#sec1-3}
==========

In each group, there were 44 patients, 30 of whom (68.2%) were male. There were no significant differences between age distribution, cigarette smoking and addiction in the study and placebo groups ([Table 1](#T1){ref-type="table"}).

###### 

Age distribution, cigarette smoking and addiction in case and placebo groups

                                            Case group Number (%)   placebo group Number (%)   p value      
  ----------------------------------------- ----------------------- -------------------------- ------------ ------
  Age (Year)                                \<45                    2 (4.5%)                   1(2.3%)      0.83
  45-60                                     15 (34.1%)              16 (36.4%)                              
  \>60                                      27 (61.4%)              27 (61.4%)                              
  Cigarette smoking (cigarette per month)   None                    11 (25%)                   13 (29.5%)   0.22
  \< 50                                     26 (59.1%)              23 (52.3%)                              
  \> 50                                     7 (15.9%)               6 (13.6%)                               
  Addiction                                 None                    17 (38.6%)                 18 (40.9%)   0.53
  Oral use                                  9 (20.4%)               8 (18.2%)                               
  Inhalation use                            16 (36.4%)              18 (40.9%)                              
  Injection use                             2 (4.5%)                0                                       

The mean of FEV1 and COPD exacerbations according to sex, age distribution, cigarette smoking and addiction, before and after the study, are shown in [Table 2](#T2){ref-type="table"} and [Table 3](#T3){ref-type="table"}.

###### 

The mean of FEV1 according to sex, age distribution, cigarette smoking and addiction, before and after the study

                                       Case        placebo                                                   
  ------------------------------------ ----------- ----------- ----------- ----------- ---------- ---------- -------
  Sex                                  Male        33.6±7.7    51.2±5.9    0.0001      33.6±4.6   33.1±9.7   0.44
  Female                               36.8±10     52.5±14.6   0.009       35±8.6      34.2±4.6   0.32       
  p value                              0.3         0.76        \-          0.17        0.59       \-         
  Age (Year)                           \<45        39±1.4      55±4.2      \-          35±0       32         \-
  45-60                                36.8±8      51±13.9     0.004       35.6±9.4    34.2±8.4   0.062      
  \>60                                 33.1±8.9    51.7±6.4    0.0001      34.5±9.2    34.8±7.7   0.13       
  p value                              0.3         0.85        \-          0.88        0.53       \-         
  Cigarettesmoking (cigarette/month)   None        35.2±8.4    49.3±15.6   0.047       38.7±9.3   34.1±6.7   0.018
  \< 50                                39.5±3.6    55.7±5.1    \<0.0001    38.7±4.4    35.7±5.4   0.011      
  \> 50                                33.07±9.1   51.5±6.4    \<0.0001    32.1±9.2    31.1±8.7   0.32       
  p value                              0.19        0.38        \-          0.063       0.31       \-         
  Addiction                            None        37±8.6      51.1±13.3   0.003       38.3±6.2   34.4±6.1   0.001
  Oral use                             37.1±7.6    54.6±5.1    \<0.0001    36.1±11.7   30±9.2     0.015      
  Inhalation use                       32.1±7.8    51.6±6.7    \<0.0001    32.6±9.7    30.2±8     0.078      
  Injection use                        34±9.8      42.5±3.5    \-          \-          \-         \-         
  p value                              0.187       0.42        \-          0.164       0.23       \-         

###### 

The mean of COPD exacerbation according to sex, age distribution, cigarette smoking and addiction, before and after the study

                                        Case       Control                                                
  ------------------------------------- ---------- ---------- ---------- ---------- ---------- ---------- -------
  Sex                                   Male       18.8±3.5   9.8±1.3    0.0001     19.3±4.2   19.6±3.9   0.056
  Female                                16.3±2.4   9.3±1.3    0.0023     18.1±2.5   17.7±2.5   0.73       
  p value                               0.095      0.25       \-         0.23       0.053      \-         
  Age (Year)                            \<45       19±1.4     10         \-         18±0       18         \-
  45-60                                 16.8±3.3   9.5±1.1    0.0001     18.8±1.4   17.8±1.6   0.79       
  \>60                                  18.2±2.8   9.7±1.5    \<0.0001   19.4±2.9   19.7±2.9   0.64       
  p value                               0.28       0.82       \-         0.66       0.069      \-         
  Cigarette smoking (cigarette/month)   None       17.1±1.9   8.8±1.3    \<0.0001   17.3±2.6   17.1±2.3   0.65
  \< 50                                 18.5±2.2   9.8±1.4    \<0.0001   19.2±3.3   19.2±2.8   0.38       
  \> 50                                 19.1±3.4   10±1.2     \<0.0001   19.1±4.4   19.4±4.1   0.89       
  p value                               0.185      0.038      \-         0.42       0.2        \-         
  Addiction                             None       16.1±2.8   9.2±1.2    \<0.0001   17.5±3.1   17.8±3.5   0.42
  Oral use                              20.4±4.7   10±1.8     \<0.0001   20±3.7     20.2±3.9   0.56       
  Inhalation use                        18.9±1.7   10±1.1     \<0.0001   19.2±4.4   19.2±3.4   0.99       
  Injection use                         15±2.1     10±1.4     \-         \-         \-         \-         
  p value                               0.023      0.35       \-         0.24       0.24       \-         

Before the study, there were no significant differences in FEV1 and the number of COPD exacerbations between the study and placebo group patients. But, after the study, there were significant differences in FEV1 and the number of COPD exacerbations between the study and placebo group patients. Also, after the study, in the study group, FEV1 was increased and the number of COPD exacerbations was decreased significantly ([Table 4](#T4){ref-type="table"}).

###### 

FEV1 and the number of COPD exacerbation in the case and placebo groups

                                        Case        Control    p value
  -------------------------- ---------- ----------- ---------- ---------
  FEV1 (M±SD)                Before     34.6±8.5    34.4±9.2   0.89
  After                      51.6±9.4   31.9±7.6    \<0.001    
  p value                    \<0.001    0.53        \-         
  COPD exacerbation (M±SD)   Before     18.02±3.3   18.7±3.8   0.38
  After                      9.7±1.3    18.8±3.6    \<0.001    
  p value                    \<0.001    0.83        \-         

4. Discussion {#sec1-4}
=============

COPD is a chronic and common disease. COPD can cause severe complications. Afonso et al., reported that 26% and 2.8% of the patients with very severe COPD and non-COPD patients had died after 1 year of follow-up in the Netherlands ([@ref1]).

An association between pulmonary function and serum vitamin D levels has been reported in some studies. It has been reported that vitamin D deficiency correlates with the severity of COPD ([@ref12]). Also, it has been reported that a significant relation between FEV1 and serum 25-hydroxy vitamin D levels ([@ref4]). However, in a study, baseline 25-hydroxy vitamin D levels were not predictive of acute exacerbation in patients with severe COPD ([@ref13]). But the relationship between vitamin D and COPD has been reported in some studies. Also, it has been stated that total vitamin D intake was negatively associated with COPD ([@ref20]). Regarding these results, vitamin D intake can be beneficial in COPD patients. This study aimed to evaluate the effect of vitamin D intake on COPD exacerbation and FEV1 in the patients with severe and very severe COPD. According to our knowledge, the effect of vitamin D on FEV1 and COPD exacerbations has been studied in few studies.

In this study, vitamin D intake improved COPD exacerbations and FEV1 in the patients with severe and very severe COPD. Hornikx et al., reported that 100.000 IU of vitamin D per month for one year had improved maximal oxygen uptake and inspiratory muscle strength significantly in the COPD subjects who had followed a rehabilitation program ([@ref11]). These findings can vindicate the results of our study.

In a similar study, Lehouck et al., compared the effects of vitamin D and placebo on FEV1 and exacerbation rate in the patients with moderate to very severe COPD ([@ref15]). In their study, each patient received 100,000 IU of vitamin D every 4 weeks for 1 year. In contrast to our results, they reported that this dose of vitamin D had not improved FEV1 and exacerbation rate. This difference may be due to the difference between baseline serum vitamin D levels in these studies. Although serum vitamin D level was not determined in our study, some studies have stated that vitamin D deficiency is prevalent in Iran. Studies suggest that Vitamin D increase production IL-10, an antiinflammatory cytokine involved in the pathogenesis of asthma, from T cells, increase production IL-37, antimicrobial peptide, regulate matrix metalloproteinases (MMP), shifting theTh1 and Th2 balance and reducing inflammation ([@ref21], [@ref7]; [@ref10]). Taken together vitamin D intake (100,000 IU per 4 weeks for 6 months) improved COPD exacerbation and FEV1 in the patients with severe and very severe COPD significantly. It is suggested that baseline serum vitamin D levels be recorded in similar studies and the effect of vitamin D intake be evaluated regarding the baseline serum vitamin D levels.
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